MichaelJNaughtonMD

Oncology • Saint Louis, MO

Assistant Professor, Internal Medicine, Washington University School of Medicine

Join to view full profile

Dr. Naughton is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Naughton's full profile

Already have an account?

Office
4921 Parkview Pl
7th Floor Suite A
Saint Louis, MO 63110
Phone+1 314-747-9281
Is this information wrong?

Education & Training

Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 1996 - 2000
Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 1996 - 1999
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1993 - 1996
Jacobs School of Medicine and Biomedical Sciences at the University at BuffaloClass of 1993

Certifications & Licensure

MO State Medical License 1996 - 2025
CA State Medical License 2015 - 2021
OH State Medical License 2000 - 2010
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012

Clinical Trials

Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) Start of enrollment: 2006 Apr 07
Active, not recruiting
Phase 3
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells Start of enrollment: 2005 Sep 14
Recruiting
Intensity Modulated Radiotherapy for Breast Cancer Start of enrollment: 2008 Jan 04
Completed
Phase 1
Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer Start of enrollment: 2008 May 15
Active, not recruiting
Phase 3
Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer Start of enrollment: 2008 Oct 13
Completed
Phase 3
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery Start of enrollment: 2009 May 15
Active, not recruiting
Phase 2
A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Start of enrollment: 2010 Aug 13
Completed
Phase 3
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer Start of enrollment: 2012 Dec 11
Completed
Phase 2
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Start of enrollment: 2013 Sep 12
Active, not recruiting
Phase 3
Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies Start of enrollment: 2013 May 07
Completed
Phase 1
LDE225 in Treating Patients With Stage II-III Estrogen Receptor- and HER2-Negative Breast Cancer Start of enrollment: 2014 Apr 01
Withdrawn
Phase 2
Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells Start of enrollment: 2013 Dec 19
Terminated
Phase 2
VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors Start of enrollment: 2013 May 03
Terminated
Phase 1, Phase 2
Paclitaxel and BKM120 Before Surgery in Treating Patients With Stage II or III Estrogen Receptor-Positive and HER2-Negative Breast Cancer Start of enrollment: 2014 Aug 01
Withdrawn
Phase 2
Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity Start of enrollment: 2014 Jul 07
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

A Phase I Study of Apolizumab, an Anti-HLA-DR ß-chain Monoclonal Antibody, in Patients With Solid Tumor Malignancies.
Paula M Fracasso, Sherry A Goodner, Jonathan D Wildi, Michael J Naughton, Gerald P Linette, Ramaswamy Govindan, Benjamin R Tan, Kristie A Blum, Gary J Jones, Tillman E...> ;American Journal of Clinical Oncology. 2022 Jul 1
4 citations
Phase I Study of Docetaxel and Temsirolimus in Refractory Solid Tumors.
Manik Amin, Feng Gao, Gretel Terrero, Joel Picus, Andrea Wang-Gillam, Rama Suresh, Cynthia Ma, Benjamin R. Tan, Maria Q. Baggstrom, Michael J. Naughton, Lauren Trull, ...> ;American Journal of Clinical Oncology. 2021 Sep 1
24 citations
Association of PET-based estradiol-challenge test for breast cancer progesterone receptors with response to endocrine therapy
Farrokh Dehdashti, Ningying Wu, Cynthia X. Ma, Michael J. Naughton, John A. Katzenellenbogen, Siegel, B. A., Barry A. Siegel> ;Nature Communications. 2021 Feb 2
8 citations
Predictors of Locoregional Recurrence After Failure to Achieve Pathologic Complete Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
Prashant Gabani, Emily Merfeld, A. Srivastava, Ashley A. Weiner, L.L. Ochoa, D. Mullen, Maria A. Thomas, Julie A. Margenthaler, Amy E. Cyr, Lindsay L. Peterson, Michae...> ;Journal of the National Comprehensive Cancer Network. 2019 Apr 1
6 citations
Treatment response as predictor for brain metastasis in triple negative breast cancer: A score-based model.
Prashant Gabani, Ashley A. Weiner, Leonel Hernandez-Aya, Shariq Khwaja, Michael C. Roach, L.L. Ochoa, D. Mullen, Maria A. Thomas, Melissa A. Matesa, Julie A. Margentha...> ;The Breast Journal. 2019 May 1
9 citations
A Pharmacogenetic Prediction Model of Progression-Free Survival in Breast Cancer using Genome-Wide Genotyping Data from CALGB 40502 (Alliance)
Sara R. Rashkin, Katherina C. Chua, Carol Ho, Flora Mulkey, Chen Jiang, Tasei Mushiroda, Michiaki Kubo, Paula N. Friedman, Hope S. Rugo, Howard L. McLeod, Mark J. Rata...> ;Clinical Pharmacology and Therapeutics. 2019 Mar 1
15 citations
Emerging Perspectives on mTOR Inhibitor‐Associated Pneumonitis in Breast Cancer
Ricardo H. Alvarez, Rabih Bechara, Michael Naughton, Javier A. Adachi, James M. Reuben> ;The Oncologist. 2018 Jun 1
46 citations
Evaluation of [ 89 Zr]trastuzumab-PET/CT in differentiating HER2-positive from HER2-negative breast cancer
Farrokh Dehdashti, Ningying Wu, Ron Bose, Michael Naughton, Cynthia X. Ma, Bernadette V. Marquez-Nostra, Philipp Diebolder, Cedric Mpoy, Buck E. Rogers, Suzanne E. Lap...> ;Breast Cancer Research and Treatment. 2018 Feb 13
57 citations
A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer
Cynthia X. Ma, César Sánchez, Feng Gao, Robert J. Crowder, Michael Naughton, Timothy J. Pluard, Allison N. Creekmore, Zhanfang Guo, Jeremy Hoog, A. Craig Lockhart, Aus...> ;Clinical Cancer Research. 2016 Jun 1
13 citations
Long-term outcomes of APBI via multicatheter interstitial HDR brachytherapy: Results of a prospective single-institutional registry.
Prashant Gabani, Amy E. Cyr, Jacqueline E. Zoberi, L.L. Ochoa, Melissa A. Matesa, Maria A. Thomas, Jose Garcia, Julie A. Margenthaler, Michael Naughton, Cynthia X. Ma,...> ;Brachytherapy. 2017 Oct 28
52 citations
A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer.
Cynthia X. Ma, Vera J. Suman, Matthew P. Goetz, Donald W. Northfelt, Mark E. Burkard, Foluso O. Ademuyiwa, Michael Naughton, Julie A. Margenthaler, Rebecca Aft, Richar...> ;Clinical Cancer Research. 2017 Nov 15
213 citations
NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer.
Cynthia X. Ma, Feng Gao, Jingqin Luo, Donald W. Northfelt, Matthew P. Goetz, Andres Forero, Jeremy Hoog, Michael Naughton, Foluso O. Ademuyiwa, Rama Suresh, Karen S. A...> ;Clinical Cancer Research. 2017 Aug 1
134 citations
Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer.
Cynthia X. Ma, Ron Bose, Feng Gao, Rachel A. Freedman, Melinda L. Telli, Gretchen Kimmick, Eric P. Winer, Michael Naughton, Matthew P. Goetz, Christy A. Russell, Debu ...> ;Clinical Cancer Research. 2017 Oct 1
23 citations
Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitor...
Kerin B. Adelson, Bhuvaneswari Ramaswamy, Joseph A. Sparano, Paul J. Christos, John J. Wright, George Raptis, Gang Han, Miguel A. Villalona-Calero, Cynthia X. Ma, Dawn...> ;NPJ Breast Cancer. 2016 Dec 14
10 citations
Impact of a behavioral weight loss intervention on comorbidities in overweight and obese breast cancer survivors
Rebecca L. Sedjo, Shirley W. Flatt, Tim Byers, Graham A. Colditz, Wendy Demark-Wahnefried, Patricia A. Ganz, Kathleen Y. Wolin, Anthony D. Elias, Helen Krontiras, Jing...> ;Supportive Care in Cancer. 2016 Mar 5
40 citations
Impact of Neoadjuvant and Adjuvant Chemotherapy on Immediate Tissue Expander Breast Reconstruction
Utku Can Dölen, Alexandra C. Schmidt, Grace Um, Ketan Sharma, Michael Naughton, Imran Zoberi, Julie Margenthaler, Terence M. Myckatyn> ;Annals of Surgical Oncology. 2016 Mar 4
4 citations
Lymphovascular space invasion and lack of downstaging after neoadjuvant chemotherapy are strong predictors of adverse outcome in young women with locally advanced brea...
Shariq Khwaja, Jennifer Ivanovich, Todd DeWees, L.L. Ochoa, D. Mullen, Maria A. Thomas, Julie A. Margenthaler, Amy E. Cyr, Michael Naughton, Souzan Sanati, Timothy J. ...> ;Cancer Medicine. 2016 Feb 1
33 citations
Quality of life outcomes from the Exercise and Nutrition Enhance Recovery and Good Health for You (ENERGY)-randomized weight loss trial among breast cancer survivors
Wendy Demark-Wahnefried, Graham A. Colditz, Cheryl L. Rock, Rebecca L. Sedjo, Jingxia Liu, Kathleen Y. Wolin, Helen Krontiras, Tim Byers, Bilge Pakiz, Barbara A. Parke...> ;Breast Cancer Research and Treatment. 2015 Oct 31
70 citations
A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer
Cynthia X. Ma, Jingqin Luo, Michael Naughton, Foluso O. Ademuyiwa, Rama Suresh, Malachi Griffith, Obi L. Griffith, Zachary L. Skidmore, Nicholas C. Spies, Avinash Ramu...> ;Clinical Cancer Research. 2016 Apr 1
135 citations
Results of the Exercise and Nutrition to Enhance Recovery and Good Health for You (ENERGY) Trial: A Behavioral Weight Loss Intervention in Overweight or Obese Breast C...
Cheryl L. Rock, Shirley W. Flatt, Tim Byers, Graham A. Colditz, Wendy Demark-Wahnefried, Patricia A. Ganz, Kathleen Y. Wolin, Anthony D. Elias, Helen Krontiras, Jingxi...> ;Journal of Clinical Oncology. 2015 Aug 17
14 citations
Effect of weight loss on bone health in overweight/obese postmenopausal breast cancer survivors.
Adetunji T. Toriola, Jingxia Liu, Patricia A. Ganz, Graham A. Colditz, Lin Yang, Sonya Izadi, Michael Naughton, Anna L. Schwartz, Kathleen Y. Wolin> ;Breast Cancer Research and Treatment. 2015 Jul 15
135 citations
Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab as First-L...
Hope S. Rugo, William T. Barry, Alvaro Moreno-Aspitia, Alan P. Lyss, Constance Cirrincione, Eleanor H. Leung, Erica L. Mayer, Michael Naughton, Deborah Toppmeyer, Lisa...> ;Journal of Clinical Oncology. 2015 Jul 20
98 citations
Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer
Shivaani Kummar, Amit M. Oza, Gini F. Fleming, Daniel M. Sullivan, David R. Gandara, Michael Naughton, Miguel A. Villalona-Calero, Robert J. Morgan, Peter M. Szabó, Ah...> ;Clinical Cancer Research. 2015 Apr 1
61 citations
Safety and Preliminary Evidence of Biologic Efficacy of a Mammaglobin-A DNA Vaccine in Patients with Stable Metastatic Breast Cancer
Venkataswarup Tiriveedhi, Natalia S Tucker, John M. Herndon, Lijin Li, Mark A. Sturmoski, Matthew J. Ellis, Cynthia X. Ma, Michael Naughton, A. Craig Lockhart, Feng Ga...> ;Clinical Cancer Research. 2014 Dec 1
3 citations
A phase I study of pegylated liposomal doxorubicin and temsirolimus in patients with refractory solid malignancies.
Andrea Wang-Gillam, Nilay Thakkar, A. Craig Lockhart, Kerry J. Williams, Maria Q. Baggstrom, Michael Naughton, Rama Suresh, Cynthia X. Ma, Benjamin R. Tan, Wooin Lee, ...> ;Cancer Chemotherapy and Pharmacology. 2014 Jun 11
Join now to see all